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Abstract
Background: Plasma d-dimer levels have been associated with the status of tumor progression or oncological
outcomes in cancer. Although there are many evidences suggesting the involvement of procoagulant trend in
musculoskeletal sarcoma, no clinical data on d-dimer levels and oncological outcome of musculoskeletal sarcoma
has been reported.
Methods: In this study, we included a total of 85 patients who were diagnosed with musculoskeletal sarcoma and
treated at our institute. Plasma d-dimer levels were determined before performing any clinical intervention,
including open biopsy, chemotherapy, radiotherapy or tumor resection. We evaluated the effect of d-dimer levels
and other clinicopathological factors on oncological outcomes of patients.
Results: Upregulation of plasma d-dimer levels proved to be an independent risk factor for metastasis and lethal
outcome of patients with musculoskeletal sarcoma.
Conclusions: Upregulation of plasma d-dimer levels were indicated poor oncological outcome in metastasis and
total survival rate of musculoskeletal sarcoma patients. Hence d-dimer levels may be a helpful marker for evaluating
the tumor progression status and prognosis of musculoskeletal sarcoma.
Background
Deterioration in the hemostatic status is one of the sig-
nificant physiological changes induced by malignant
condition. The close relationship between cancer and
thrombosis has been clinically well established. Indeed,
the risk of venous thromboembolism is higher in cancer
patients than in non-cancer patients [1].
Various kinds of procoagulant factors such as malig-
nant condition itself, chemotherapy, long rest period,
pathological fracture, orthopedic surgery, and recon-
struction by prosthesis or plastic surgery, have been
associated with musculoskeletal sarcoma. Indeed, the
incidence of venous thromboembolism caused by sys-
temic activation of clotting-fibrinolytic system in muscu-
loskeletal sarcoma patients is considerably high [2-5].
Direct or collateral evidences suggested the involve-
ment of procoagulant molecular mechanisms in
musculoskeletal sarcoma. Some examples are as follows.
(1) Tissue factor (TF) is a key factor in thrombin gen-
eration/fibrin formation and regulates procoagulant
activity in many cancer tissues [1,6,7]. This molecule
has been reported to be upregulated in a human osteo-
sarcoma cell line [8]. (2) Fibrinolytic molecules that reg-
ulate fibrinolytic pathway in tumor tissue include
urokinase type plasminogen activator, urokinase type
plasminogen activator receptor, and plasminogen activa-
tor inhibitors [1]. The expression of these fibrinolytic
molecules was reported to be changed in musculoskele-
tal malignancy [9,10]. (3) Tumor cells secrete various
proinflammatory or proangiogenic cytokines such as
tumor necrosis factor-alpha, interleukin-1 beta or vascu-
lar endothelial growth factor (VEGF), which may affect
the anticoagulant system [1]. There is a close relation in
the expression and function between VEGF and TF
[11,12]. Upregulation of VEGF has been widely reported
in musculoskeletal malignancy [13].
D-dimer, a degradation product of cross-linked fibrin
blood clots, is an indicator of fibrin concentration.
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in several procoagulant pathophysiological conditions,
including cancer. Recent studies revealed that plasma d-
dimer levels could be used to determine tumor stage/
grade [2,14-17], disease progression/response to treat-
ment [18,19], or oncological outcome [17,20,21]. How-
ever, the relevance of d-dimer levels as a prognostic
factor of musculoskeletal sarcoma has not yet been
established thus far. On the basis of the abovementioned
data, we hypothesized that plasma d-dimer levels in
musculoskeletal sarcoma patients were indicators of
tumor progression and oncological outcome, and we
analyzed the effect of d-dimer levels on metastasis and
lethal outcome in order to establish the clinical signifi-
cance of d-dimer levels as a prognostic marker.
Methods
We designed a retrospective uncontrolled study based
on data obtained from medical records. The inclusion
criteria for this study were as follows: (1) musculoskele-
tal sarcoma diagnosed and treated at our institute
between 2006 and 2010; (2) patients who had undergone
standard oncological resection [22]; (3) adequate clinical
information in the records; and (4) at least 12 months
follow-up, except in the case of death before that time.
Patients were excluded if the presence of any of the fol-
lowing was identified at the time of presentation: (1) evi-
dent metastases; (2) pathological fracture; (3) pre-
existing hypercoagulopathy; (4) recent anticoagulant
therapy including prophylaxis of thromboembolic com-
plications; (5) recent trauma; (6) inflammatory diseases;
and (7) other major surgery recently performed. Finally,
85 patients who met these criteria were included in this
study. Clinicopathological and demographic variables of
this cohort are summarized in Table 1.
Adjuvant and neoadjuvant systemic chemotherapy
were performed in less than 65 years old patients with
high grade sarcoma. The treatment regimens were
selected based on the histological findings of the
patients [23-25]. Radiotherapy was performed postopera-
tively only for 6 patients in whom postoperative patho-
logical evaluation suggested microscopic residual
tumors. Histological grade and surgical margin was
determined as previously described [22]. Tumor relapse
was detected by physical examination of the tumor site
and regional lymph node and by computed tomography
Table 1 Characteristics of the patients
Age (year) Mean 55.7
Range 9-95
Sex Male 38 (44.7%)
Female 47 (55.3%)
Location Upper extremity 14 (16.5%)
Lower extremity 47 (55.3%)
Trunk 24 (28.2%)
Extension Intracompartmental 36 (42.4%)
Extracompartmental 49 (57.6%)
Tumor size (mm) Mean 87.0
Range 20-308
Diagnosis Bone 19
Osteosarcoma 10 (11.8%)
Chondrosarcoma 8 (9.4%)
Others 1 (1.2%)
Soft tissue 67
Liposarcoma 23 (27.1%)
Undifferentiated pleomorphic sarcoma 14 (16.5%)
Leiomyosarcoma 7 (8.2%)
Malignant peripheral nerve sheath tumor 5 (5.9%)
Others 17 (20.0%)
Grade High 48 (56.5%)
Low 37 (43.5%)
Surgical margin Adequate 74 (87.1%)
Inadequate 11 (12.9%)
Follow up period (months) Mean 23.0
Range 6-50
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up period was 23.0 (6-50) months.
Plasma d-dimer levels were assessed before performing
any kind of intervention for tumor, including che-
motherapy, radiotherapy, open biopsy, or tumor resec-
tion. For the measurement of d-dimer levels, a latex
agglutination assay (STA Liatest
® D-Di (Roche Diagnos-
tics AG, Rotkreuz, Switzerland), which was performed
on the STA-R
® coagulation analyzer) was peformed
[2,3]. On the basis of the sensitivity of this assay, levels
< 0.20 μg/ml were considered as 0.20 μg/ml.
The endpoints of this study were local recurrence,
metastasis, and total survival. The independent risk fac-
tors in the present study were patient’ age, sex, anatomic
site, tumor origin (bone vs soft tissue), histological
grade, extracompartment extension, tumor size, surgical
margin, and d-dimer levels on referral.
Statistical analysis was performed using the receiver
operating characteristic (ROC) curve analysis, Kaplan-
Meier methods, log-rank tests, and Cox proportional
hazards model with JMP (version 7; SAS institute Inc.,
North Carolina, USA). The differences were considered
significant when p < 0.05. For multivariate analysis, cov-
ariates with a p value of less than 0.05 were retained in
the final model. The study was approved by the institu-
tional review board of the authors institution.
Results
The d-dimer levels ranged from 0.2 to 8.3 μg/ml (mean,
0.84 μg/ml; median, 0.42 μg/ml). In order to determine
the cut off value of d-dimer levels in this analysis, we
performed ROC curve analysis (Figure 1). The areas
under the curve (AUC) were 0.437 for local recurrence,
0.712 for metastasis and 0.749 for total survival, suggest-
ing that there was no evident difference in the levels of d-
dimer in patients with and without local recurrences;
hence, local recurrence was deleted from the endpoints
of this study. The optimal cut off value of d-dimer was
determined at the point on ROC curve at which (sensitiv-
ity+specificity-1) was maximized (Youden index). For
metastasis, optimal cut off value of d-dimer was 0.41 μg/
ml with which sensitivity and specificity were 0.83 and
0.57, respectively. In a similar way for total survival, opti-
mal cut off value of d-dimer was 0.80 μg/ml with which
sensitivity and specificity were 0.80 and 0.75, respectively.
Next, the effect of independent variables, including d-
dimer levels, on the 2 endpoints, namely, metastasis and
total survival, was analyzed by using survival analysis
model. The result of univariate analysis suggested that
elevated d-dimer levels (p = 0.002) (Figure 2A) and his-
tological grade (p = 0.009) were the significant risk fac-
tors for metastases (Table 2); further, elevated d-dimer
levels (p = 0.0004) (Figure 2B), histological grade (p =
0.03), and extracompartmental extension of the tumor
(p = 0.04) were the significant risk factors for lethal out-
come (Table 3). Multivariate analysis results suggested
that both elevated d-dimer levels (p = 0.003) and histo-
logical grade (p = 0.01) were the independent risk fac-
tors for metastases, and elevated d-dimer levels (p =
0.004) and extracompartmental extension of the tumor
(p = 0.04) were the independent risk factors for lethal
outcome.
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Figure 1 The receiver operating characteristic curve analysis. The receiver operating characteristic (ROC) curve analysis was performed in
order to determine the cut off value of d-dimer levels. A. Local recurrence. B. Metastasis. C. Tumor specific death. The optimal cut off value of d-
dimer was determined at the point on ROC curve at which (sensitivity+specificity-1) was maximized (Youden index). For metastasis, optimal cut
off value of d-dimer was 0.41 μg/ml with which sensitivity and specificity were 0.83 and 0.57, respectively. In a similar way for total survival,
optimal cut off value of d-dimer was 0.80 μg/ml with which sensitivity and specificity were 0.80 and 0.75, respectively.
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Musculoskeletal sarcoma is a group of rare heteroge-
neous tumors of the mesenchymal lineage. Innovation
in treatment modality, including theory in determining
safety margin, limb salvage procedure and systemic che-
motherapy have improved oncological outcomes of mus-
culoskeletal sarcoma over the past 3 decades [22].
Accumulated clinical data suggested that several clinico-
pathological factors, including histological grade, tumor
size, surgical margin, tumor extension, and age are prog-
nostic factors of oncological outcome [22,26,27]. In
order to evaluate the biological properties of musculos-
keletal sarcoma, additional markers are being intensively
investigated.
D-dimer is a degradation product of cross-linked fibrin
blood clots and indicates fibrin concentration. We have
previously shown that plasma d-dimer levels were closely
related to the histological grade of musculoskeletal tumor
Figure 2 Kaplan-Meier survival curve. Kaplan-Meier survival curve showing the effect of d-dimer level on metastasis (A) and the total survival
rate (B).
Table 2 Risks for metastasis
Variables Subclass Event Cases Univariate analysis Multivariate analysis
p p Hazard ratio 95% Confidence interval
Age ≧ 56 years 8 42 0.54
< 56 years 10 43
Sex Male 12 47 0.24
Female 6 38
Site Upper extremity 2 14 0.72
Lower extremity 11 47
Trunk 5 24
Origin Bone 6 19 0.20
Soft tissue 12 66
Histological grade Low 3 37 0.009 0.01 3.9 1.2-16.9
High 15 48
Extracompartment extension No 5 36 0.15
Yes 13 49
Tumor size ≧ 50 mm 13 57 0.58
<5 0m m 5 2 8
Surgical margin Adequate 15 74 0.56
Inadequate 3 11
D-dimer levels ≧ 0.41 μg/ml 15 44 0.002 0.003 5.0 1.6-21.7
< 0.41 μg/ml 3 41
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the prognostic relevance of plasma d-dimer levels in
musculoskeletal sarcoma. This is the first report showing
a close relation between d-dimer levels and oncological
outcomes in musculoskeletal sarcoma. In contrast to the
result of our previous study, multivariate analysis in this
study revealed that d-dimer levels and tumor grade were
independent factors. However we were not able to pre-
cisely determine the mechanism underlying this result.
We believe that d-dimer levels might represent the state
of disease progression itself rather than tumor properties
represented by genetic changes or morphologic findings.
Musculoskeletal malignancy is characterized by het-
erogeneity in tumor site and patients age, which may be
independent from its biological properties that are regu-
lated by genetic change. Our previous data [2] and ana-
lysis of the present cohort (data not shown) suggested
that d-dimer levels were significantly upregulated in the
elder patient group or downregulated in upper extremity
cases. If d-dimer level was significant prognostic factor
and the abovementioned close relations between the fac-
tors were true, patient age and tumor site might indeed
be the prognostic factors in this cohort. Hence, these
factors were entered into the independent variables in
the present model, which confirmed that these factors
had little effect on oncological outcome than the d-
dimer levels.
In this study, chemotherapy was indicated strictly on
the basis of grade/histological subtype of the tumor and
patient age. The results of preliminary statistical analysis
suggested a strong association between tumor grade and
indication of adjuvant chemotherapy (p = 0.001, Fisher’s
exact test) and between age and indication of adjuvant
chemotherapy (p = 0.0002, Mann-Whitney U test), sug-
gesting that the application of chemotherapy might
serve as a confounding bias. Thus, we did not include
application of adjuvant chemotherapy as independent
risk factor in survival analysis. In addition, limited num-
ber of patients received radiotherapy, and thus, indica-
tion of radiotherapy was not considered as risk factor.
The merits of the application of d-dimer levels for
predicting oncological outcome in clinical practice was
previously shown [17] as being not time and cost effi-
cient, requirement of only small plasma aliquots, and
less invasive technique. Thus, we proposed the usage of
this modality in evaluation of musculoskeletal sarcoma
patients. The limitations of this study are considerably
small sample size and candidate bias caused by procoa-
gulant factors, for example, smoking or obesity, which
were not evaluated in this study. In addition, it is neces-
sary to validate the cut off value of d-dimer. Thus, accu-
mulation of data from prospective study with a large
sample might be needed in the future.
Conclusions
Upregulation of plasma d-dimer levels indicated poor
oncological outcome in metastasis and total survival rate
of musculoskeletal sarcoma patients. D-dimer levels may
Table 3 Risks for lethal outcome
Variables Subclass Event Cases Univariate analysis Multivariate analysis
p p Hazard ratio 95% Confidence interval
Age ≧ 56 years 4 42 0.42
< 56 years 6 43
Sex Male 7 47 0.34
Female 3 38
Site Upper extremity 1 14 0.54
Lower extremity 6 47
Trunk 3 24
Origin Bone 4 19 0.14
Soft tissue 6 66
Histological grade Low 1 37 0.03 0.01 3.9 1.2-16.9
High 9 48
Extracompartment extension No 1 36 0.04 0.04 5.9 1.1-110
Yes 9 49
Tumor size ≧ 50 mm 8 57 0.29
<5 0m m 2 2 8
Surgical margin Adequate 7 74 0.12
Inadequate 3 11
D-dimer levels ≧ 0.8 μg/ml 8 44 0.0004 0.004 7.3 1.8-49
< 0.8 μg/ml 2 41
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sion status and prognosis of musculoskeletal sarcoma.
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